Top Markets
Coin of the day
Sanofi Sanofi

Sanofi

SNY
Kedudukan dalam Saham #178
Sanofi, together with its subsidiaries, engages in the research, development,... Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Harga Saham
$44.60
Modal Pasaran
$108.62B
Perubahan (1 hari)
-1.63%
Perubahan (1 tahun)
-21.62%
Negara
FR
Perdagangan Sanofi (SNY)

Kategori

Nisbah P/E bagi Sanofi (SNY)
Nisbah P/E pada March 2026 TTM: 8.78
Menurut laporan kewangan dan harga saham terkini Sanofi, nisbah P/E semasa (TTM) ialah 8.78. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 21.10.
Sejarah nisbah P/E bagi Sanofi dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 8.78 -32.02%
2025 12.92 -38.76%
2024 21.10 1.40%
2023 20.81 54.85%
2022 13.44 -24.64%
2021 17.83 122.16%
2020 8.02 -79.90%
2019 39.92 82.18%
2018 21.91 -5.40%
2017 23.16 10.24%
2016 21.01 -12.27%
2015 23.95 5.61%
2014 22.68 -17.39%
2013 27.45 44.75%
2012 18.97 43.94%
2011 13.18 -8.09%
2010 14.34 4.92%
2009 13.66 65.17%
2008 8.27 -48.59%
2007 16.09 -32.21%
2006 23.74 -45.86%
2005 43.84 -317.87%
2004 -20.12 -199.40%
2003 20.24 -15.94%
2002 24.08 -37.41%
2001 38.47 -26.60%
2000 52.42 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
42.86 388.04%
US
28.47 224.13%
GB
21.88 149.17%
US
92.55 953.80%
US
20.85 137.40%
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.